-
Mashup Score: 2Adjuvant Ibandronate Plus Capecitabine Does Not Significantly Improve OS in Elderly Patients With Early Breast Cancer - 10 month(s) ago
Although adjuvant treatment with ibandronate plus capecitabine resulted in a numerical improvement in overall survival vs ibandronate alone in elderly patients with moderate or high-risk early breast cancer, this did not reach statistical significance, according to long-term data from the phase 3 ICE study.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Adjuvant Ibandronate Plus Capecitabine Does Not Significantly Improve OS in Elderly Patients With Early Breast Cancer - 10 month(s) ago
Although adjuvant treatment with ibandronate plus capecitabine resulted in a numerical improvement in overall survival vs ibandronate alone in elderly patients with moderate or high-risk early breast cancer, this did not reach statistical significance, according to long-term data from the phase 3 ICE study.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Long-term data from the phase 3 ICE study showed that the OS improvement achieved with ibandronate plus capecitabine vs ibandronate alone was more pronounced in the HR–negative patient subgroup. @myESMO #ESMOBreast23 #bcsm https://t.co/8RGf09uaLC https://t.co/TUjwLCl45W
-
-
Mashup Score: 1Adjuvant Ibandronate Plus Capecitabine Does Not Significantly Improve OS in Elderly Patients With Early Breast Cancer - 10 month(s) ago
Although adjuvant treatment with ibandronate plus capecitabine resulted in a numerical improvement in overall survival vs ibandronate alone in elderly patients with moderate or high-risk early breast cancer, this did not reach statistical significance, according to long-term data from the phase 3 ICE study.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adjuvant Ibandronate Plus Capecitabine Does Not Significantly Improve OS in Elderly Patients With Early Breast Cancer @myESMO #ESMOBreast23 #bcsm https://t.co/szK0YDuoVo
-
-
Mashup Score: 3HER3-Targeting Antibody-Drug Conjugates Show Encouraging Results in Breast Cancer Subtypes - The ASCO Post - 11 month(s) ago
Early-phase data from the SOLTI TOT-HER3 and ICARUS-BREAST01 trials suggest that the novel HER3-directed antibody-drug conjugate patritumab deruxtecan may have beneficial activity in patients with hormone receptor–positive/HER2-negative and triple-negative breast cancer subtypes, according to research presented at the European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
HER3-Targeting Antibody-Drug Conjugates Show Encouraging Results in Breast Cancer Subtypes https://t.co/gHv6GSPo68 #bcsm #breastcancer #oncology #ESMOBreast23
-
-
Mashup Score: 0Two Studies of Atezolizumab-Based Regimens in Early-Stage, Triple-Negative and HER2-Positive Breast Cancers - The ASCO Post - 11 month(s) ago
Immunotherapy regimens involving the PD-L1 monoclonal antibody atezolizumab have demonstrated promising results in patients with early-stage, triple-negative breast cancer and HER2-positive breast cancer, according to a pair of studies presented at the European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress 2023,1,2 but additional evidence on the use of this agent in the early…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Two Studies of Atezolizumab-Based Regimens in Early-Stage, Triple-Negative and HER2-Positive Breast Cancers https://t.co/MbnePslENQ #ESMOBreast23 #bcsm #breastcancer #TNBC #oncology
-
-
Mashup Score: 1Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer - 11 month(s) ago
Atezolizumab in combination with trastuzumab and vinorelbine generated responses and a tolerable safety profile in patients with HER2-positive, estrogen receptor–negative or ER-positive/PAM50 non-luminal advanced breast cancer, according to data from a prespecified interim analysis of the phase 2 ATREZZO trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer @hospital12Oct @myESMO #ESMOBreast23 #bcsm https://t.co/eK7P01l1gR
-
-
Mashup Score: 0
Combined treatment with capivasertib plus fulvestrant yielded a 5.5-month median progression-free survival for patients with HR+ advanced breast cancer.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Combined treatment with capivasertib plus fulvestrant yielded a 5.5-month median progression-free survival for patients with HR+ advanced breast cancer. #bcsm #breastcancer #oncology #nursing #ESMOBreast23 https://t.co/UjBzUNcnQQ https://t.co/SrQs5gO3nH
-
-
Mashup Score: 0ADCs in early breast cancer - 12 month(s) ago
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, Korea, comments on how the use of antibody-drug conjugates is now being…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥Sung-Bae Kim, MD, PhD of @AsanMedicalCtr, highlights the expanding horizons of ADCs in #BreastCancer treatment. From metastatic to early and residual disease settings, their safety and efficacy are being explored: ➡️https://t.co/XxyCjr6TI8⬅️ #ESMOBreast23 #BCSM #ImmunoOnc
-
-
Mashup Score: 0Patients With De Novo or Late Recurrent Metastatic HR+ Breast Cancer Derive OS Benefit From Ribociclib/Letrozole - 12 month(s) ago
A subgroup analysis showed that patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy achieved better outcomes with ribociclib plus letrozole.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy achieved better outcomes with ribociclib plus letrozole. #oncology #nursing #bcsm #ESMOBreast23 https://t.co/AW83hk4orx
-
-
Mashup Score: 0Olaparib Delivers PFS Benefit to Patients with gBRCA+, HER2– Metastatic Breast Cancer, Independent of ER Status - 12 month(s) ago
A post-hoc analysis suggests that olaparib may extend progression-free survival in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer, no matter their estrogen receptor expression level.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A post-hoc analysis suggests that olaparib may extend PFS in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer, no matter their estrogen receptor expression level. #breastcancer #oncology #nursing #ESMObreast23 @myESMO https://t.co/x1muyQCD2Q
-
Although adjuvant treatment with ibandronate plus capecitabine numerically improved OS vs ibandronate alone in elderly patients with moderate or high-risk early breast cancer, this did not reach statistical significance. @myESMO #ESMOBreast23 #bcsm https://t.co/2auxSuQh0I